×
Customize
?
Start
Cancer Types
Quick Links
Award Programs
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873
Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.
Immunotherapy
Lowell Hart
With new ways to treat chemotherapy-induced side effects, it seems that chemotherapy, combined with checkpoint inhibitors, is here to stay for the foreseeable future, according to one expert.
Dr. Daniel McFarland
Tumor mutation burden may be an independent predictor of developing depression in patients with lung cancer, according to Dr. Daniel McFarland.
Kristie L. Kahl
Increased tumor mutation burden (TMB), which is associated with more inflammation, may be a factor in determining which patients with lung cancer are at higher risk for depression.
Jessica Skarzynski
The growing use of immunotherapy in oncology has confronted many community practice-based oncologists with challenges to implementation, but one advocacy group’s new initiative aims to educate and empower.
Katie Kosko
Autoimmune skin toxicities in patients with non-small cell lung cancer mean patients may respond better to immune checkpoint inhibitors.
Katie Kosko
Recent study findings show no significant difference in treatment efficacy or overall survival between men and women.
Dr. Jyoti Patel and patient Laura O’Brien share their parting perspectives on stage III non-small cell lung cancer and the future of treatment.
The value of support and credible information is emphasized regarding one’s journey through non-small cell lung cancer.
Together with Dr. Jyoti Patel, Laura O’Brien shares insight on her experience of receiving immunotherapy for stage III non-small cell lung cancer.
Laura O’Brien elucidates her experience of enrolling on a clinical trial following her diagnosis of stage III non-small cell lung cancer.